AMS BIOTECHNOLOGY (EUROPE) LTD.

History

Year	Detail
1987	Founded in 1987, AMSBIO is a life sciences supplier that provides products and services for research and development in the medical, nutrition, cosmetics, and energy industries.
2003	The company started offering custom services, including monoclonal antibody production, custom protein expression, and polyclonal antibody services.
2011	AMSBIO acquired the Seikagaku Corp's reagents and glycobiology biochemicals portfolio.
2017	The company partnered with Dr. Michele Zagoni to launch ScreenIn 3D, a patented lab-on-a-chip technology for screening patient-derived tumor models.
2021	The company established its offices in the Netherlands to serve European customers after the U.K. left The European Union.
2023	AMSBIO launched a new extracellular matrix product range for 3D cell culture and PRCC.
2023	The company acquired cells diagnostics and biotech company Genlantis Inc.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment